Ischemic Cardiomyopathy Clinical Trial
Official title:
Comparison Between Coronary Revascularization Based on CMR Viability Study Vs Direct Revascularization in Patients With Ischemic Cardiomyopathy
The study aiming to demonstrate the baseline characteristics and outcomes of patients undergoing revascularization by PCI vs those kept only on medical treatment, based on CMR viability assessment.
Cardiac magnetic resonance (CMR) has an ever-increasing role in the assessment and management of patients with coronary artery disease (CAD). Advantages of CMR include the lack of ionizing radiation and its flexibility, high spatial resolution, and three-dimensional capabilities that enable imaging in any desired plane. In the evaluation of patients with ischemic cardiomyopathy, CMR is primarily used in the setting of chronic CAD for the evaluation of myocardial ischemia and viability. Left ventricular systolic dysfunction, resulting from coronary artery disease is reversible with revascularization in cases of hibernation and stunned myocardium. Revascularization is dependent not only on the presence but also the extent of viability, and a viable myocardium is necessary for functional recovery. In a CMR study, in areas with dysfunctional myocardium as detected in cine sequences, the end diastolic wall thinning >5.5 mm, the extent of subendocardial fibrosis together with response to low dose dobutamine were shown to predict functional recovery. However, in the famous viability sub study of the STICH (Surgical Treatment for Ischemic Heart Failure) trial, there was a significant association between myocardial viability and outcome by univariate analysis, but not on multivariable analysis. Thereby, the value of CMR in this regards is still debatable. So, according to the recent state of art paper from the American Heart Association, data is still limited regarding CMR use to guide revascularization strategies or predict outcomes in patients with severe LV dysfunction. The statement recommended that future trials should continue to address the clinical impact of specific modality-based strategies or multimodality strategies in guiding treatment in terms of patient outcomes. On the other hand, appropriately guided coronary revascularization may go beyond providing recovery of myocardial systolic contractility by improving patient's functional class and heart failure symptoms, enhancing diastolic relaxation, reducing the burden of rhythm abnormalities, or decreasing the burden of polypharmacy, thereby reducing the risk of drug toxicity and improving quality of life. These additional benefits need also to be explored in clinical trials. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04066738 -
Scar Location and Acute Haemodynamic Response to MultiPoint Pacing Study in Patients With Ischemic Cardiomyopathy
|
N/A | |
| Recruiting |
NCT03536052 -
Ablation at Virtual-hEart pRedicted Targets for VT
|
N/A | |
| Enrolling by invitation |
NCT02930265 -
Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy
|
N/A | |
| Completed |
NCT01215253 -
Ranolazine Implantable Cardioverter-Defibrillator Trial
|
Phase 3 | |
| Completed |
NCT04508608 -
Scintigraphic Evaluation of Contractile and Coronary Reserve in Patients With Ischemic Cardiomyopathy
|
||
| Recruiting |
NCT05888662 -
Endo-epicardial vs Endocardial-only Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy (EPIC-VT)
|
N/A | |
| Completed |
NCT03857906 -
Evaluation of Prophylactic Use of a Preoperative IABP in High-Risk Coronary Artery Bypass Graft Surgery
|
||
| Completed |
NCT02501811 -
Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure
|
Phase 2 | |
| Recruiting |
NCT02058771 -
Utilising Lifemap to Investigate Malignant Arrhythmia Therapy
|
||
| Not yet recruiting |
NCT01946048 -
Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Ischemic Cardiomyopathy
|
Phase 1 | |
| Terminated |
NCT01759212 -
Left Ventricular Assist Device Combined With Allogeneic Mesenchymal Stem Cells Implantation in Patients With End-stage Heart Failure.
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT01447069 -
Use of Beta-agonists in Stable Severe Congestive Heart Failure
|
N/A | |
| Recruiting |
NCT00972114 -
CABG Combined Pedicled Omentum Wrapped Autologous Atrial Tissue Patch Cardiomyoplasty for Ischemic Cardiomyopathy
|
Phase 1/Phase 2 | |
| Completed |
NCT00896142 -
Optima Coronary Artery Disease (CAD) (Optimal Mechanical Evaluation)
|
N/A | |
| Recruiting |
NCT01076660 -
Left Ventricular Structural Predictors of Sudden Cardiac Death
|
||
| Completed |
NCT00305214 -
MASTER II - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients
|
N/A | |
| Completed |
NCT00305240 -
MASTER I - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients
|
N/A | |
| Active, not recruiting |
NCT00962364 -
Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease
|
||
| Recruiting |
NCT05769036 -
Conventional Biventricular Versus Left Bundle Branch Pacing on Outcomes in Heart Failure Patients
|
N/A | |
| Completed |
NCT03862339 -
The SoundScar Study The SOUNDSCAR Study
|